Showing 2921-2930 of 6036 results for "".
- EyePoint Pharmaceuticals Presents Positive Data of Yutiq and Dexycu in Four Poster Sessions at AAO 2020https://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-data-of-yutiq-and-dexycu-in-four-poster-sessions-at-aao-2020/2478559/EyePoint Pharmaceuticals announced that positive data for Yutiq and Dexycu were featured in four presentations at the recent American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Data presented included: Statistically significant effi
- iSTAR Medical’s Glaucoma Device MINIject Shows Positive One-Year Results in European Trialhttps://modernod.com/news/istar-medicals-glaucoma-device-miniject-shows-positive-one-year-results-in-european-trial/2478552/iSTAR Medical announced positive 1-year results from the European STAR-II clinical trial of its micro-invasive glaucoma surgery (MIGS) device, MINIject. The results have been presented at the virtual American Academy of Ophthalmology (AAO) annual meeting, held November 13-15 2020. Po
- Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Material Recycled Through One By One Recycling Programhttps://modernod.com/news/bausch-lomb-reports-nearly-27-million-united-of-contact-lens-material-recycled-through-one-by-one-recycling-program/2478541/Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and blister packs since launching in November 2016. The program, made possible through a collaboration with TerraCycle, a leader in the collection and repurposing
- Leo Lens Pharma Achieves FDA IND Submission and Seed Round Fundraisinghttps://modernod.com/news/leo-lens-pharma-achieves-fda-ind-submission-and-seed-round-fundraising/2478530/Leo Lens Pharma announced the achievement of two milestones: the filing of the FDA’s investigational new drug (IND) application for its lead asset, a proprietary drug-eluting, comfort-enhancing contact lens to treat patients suffering from primary open-angle glaucoma or ocular hy
- Lensar to Present Several Papers at 2020 AAO Virtual Meetinghttps://modernod.com/news/lensar-to-presents-several-papers-at-2020-aao-virtual-meeting/2478513/Lensar announced the following posters/papers were accepted to be presented at the 2020 AAO Virtual Meeting taking place Nov. 13-15. 2020 AAO Accepted Posters/Papers Company Ty
- Hoya Surgical Optics Introduces On-Demand Platform Qube Pro Powered by Eyeflexahttps://modernod.com/news/hoya-surgical-optics-introduces-on-demand-platform-qube-pro-powered-by-eyeflexa/2478514/Hoya Surgical Optics obtained CE Mark for “Qube pro powered by eyeflexa,” a technology that can support both cataract and vitreoretinal surgery. Eyeflexa is a multi-upgrade platform designed to evolve with the changing needs of ophthalmic surgeons, according to a company news r
- Avellino Introduces Multiplex Respiratory Panel for Simultaneous Detection of COVID-19 and Influenzahttps://modernod.com/news/avellino-introduces-multiplex-respiratory-panel-for-simultaneous-detection-of-covid-19-and-influenza/2478505/Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the FDA’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines. The AvellinoCoV
- Technique to Regenerate Optic Nerve Offers Hope for Future Glaucoma Treatmenthttps://modernod.com/news/technique-to-regenerate-optic-nerve-offers-hope-for-future-glaucoma-treatment/2478496/Scientists have used gene therapy to regenerate damaged nerve fibres in the eye, in a discovery that could aid the development of new treatments for glaucoma, according to a Medical Xpress report. </
- Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement for Dextenza and OTX-TIC in Asiahttps://modernod.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of post-surgical ocul
- CVS Pharmacy Launches QuickRenew At-Home Contact Lens Prescription Renewal Toolhttps://modernod.com/news/cvs-pharmacy-launches-quickrenew-at-home-contact-lens-prescription-renewal-tool/2478465/CVS Pharmacy announced the launch of QuickRenew, an online contact lens prescription renewal tool currently available on the